openPR Logo
Press release

Behçet's Disease Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

12-15-2023 11:11 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Behçet's Disease Pipeline

Behçet's Disease Pipeline

DelveInsight's, "Behçet's Disease Pipeline Insight 2023" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Behçet's Disease pipeline landscape. It covers Behçet's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers Behçet's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Behçet's Disease Pipeline Report
• DelveInsight's Behçet's Disease pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Behçet's Disease treatment.
• The leading companies working in the Behçet's Disease Market include AbbVie, Eisai Co. Ltd, Nobel Pharmaceuticals, Ainos Inc., Amgen, Janssen Korea Ltd, Novartis Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Hoffmann-La Roche, Bristol-Myers Squibb, Abott, Sanguine Biosciences, GlaxoSmithKline, and others.
• Promising Behcet's Disease Pipeline Therapies in the various stages of development include Adalimumab, Veldona, Apremilast, Infliximab, Canakinumab, Pentoxifylline, TA-650, AIN457, Cytotoxic Combination, Abatacept, and others.
• December 2023: Amgen announced a study of Phase 3 clinical trials for Apremilast. The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.
• August 2023: Amgen announced a study of Phases 3 Clinical Trials for Apremilast. The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.
• August 2023: Ipekyolu Ilac Ltd. Sti announced a study of Phase 2 Clinical Trials for Pentoxifylline and Colchicine. Although Behçet's Disease (BD) has no FDA-approved therapies, numerous clinical reports suggest that oral ulcers of BD may resolve when treated with systemic ingested pentoxifylline (PTX). The investigators here propose to investigate the therapeutic potential of PTX dissolved in muco-adherent formulation and directly applied to the oral lesions. This 60 patient proof of concept trial is designed to meet regulatory requirements for safety concerns while at the same time exploring the potential efficacy and clinical utility of this product.

Request a sample and discover the recent advances in Behçet's Disease Treatment Drugs @ Behçet's Disease Pipeline Report- https://www.delveinsight.com/report-store/behcet-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Behçet's Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Behçet's Disease clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Behçet disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Behçet's Disease Overview
Behcet disease was first described in 1937 by Hulusi Behçet from Istanbul, who described three patients with oral and genital ulcerations, uveitis, and erythema nodosum. Other clinical features were identified later and were added to the disease spectrum. Behcet disease is an auto-inflammatory systemic vasculitis of unknown etiology.

Find out more about Behçet's Disease Therapeutics Assessment @ Behçet's Disease Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/behcet-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Behçet's Disease Emerging Drugs Profile
• Canakinumab: Novartis

Behçet's Disease Pipeline Therapeutics Assessment
There are approx. 5+ key Behçet's Disease Companies which are developing the Behçet's Disease therapies. The Behçet's Disease companies which have their Behçet disease drug candidates in the most advanced stage, i.e. Phase II include Novartis.

Learn more about the emerging Behçet's Disease Pipeline Therapies @ Behçet's Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/behcet-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Behçet's Disease Pipeline Report
• Coverage- Global
• Behçet's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Behçet's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Behçet's Disease Companies- AbbVie, Eisai Co. Ltd, Nobel Pharmaceuticals, Ainos Inc., Amgen, Janssen Korea Ltd, Novartis Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Hoffmann-La Roche, Bristol-Myers Squibb, Abott, Sanguine Biosciences, GlaxoSmithKline, and others.
• Behcet's Disease Pipeline Therapies- Adalimumab, Veldona, Apremilast, Infliximab, Canakinumab, Pentoxifylline, TA-650, AIN457, Cytotoxic Combination, Abatacept, and others.

Dive deep into rich insights for new drugs for Behçet's Disease Treatment, Visit @ Behçet's Disease Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/behcet-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Behçet disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Behçet disease- DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. Canakinumab: Novartis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Cipargamin: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. KPG612: Kangpu Biopharmaceuticals
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Behçet disease Key Companies
24. Behçet disease Key Products
25. Behçet disease- Unmet Needs
26. Behçet disease- Market Drivers and Barriers
27. Behçet disease- Future Perspectives and Conclusion
28. Behçet disease Analyst Views
29. Behçet disease Key Companies
30. Appendix

For further information on the Behçet's Disease Pipeline therapeutics, reach out to Behçet's Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/behcet-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Important Published Links

https://scocial-online.mn.co/posts/46864423
https://akb.tribe.so/post/behcet-s-disease-a-rare-and-chronic-inflammatory-condition-has-long-posed-c--6576dd3288d020256754898b
https://www.sutori.com/en/denny-dones?tab=profile
https://network-96590.mn.co/posts/46865392
https://lean-in-bay-area.mn.co/posts/46865790
https://network-88594.mn.co/posts/46865905
https://decide.mn.co/posts/46866036
https://jomijomig.mn.co/posts/46866708
https://constantlycheeky.mn.co/posts/46867239
https://www.vwvortex.com/members/ybhardwaj.3957496/#about
https://redline-rp.mn.co/posts/46868784
https://forum.eset.com/profile/88964-denny-dones/?tab=field_core_pfield_11
https://en.pinkoi.com/user/gg_116344212900924579142
https://dennydones9.diary.ru/
https://slideslive.com/ewkwsgtt7o?tab=about
https://dennydones.substack.com/p/behcets-syndrome-market-size-in-the?r=33xju7&utm_campaign=post&utm_medium=web

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Behçet's Disease Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 here

News-ID: 3329048 • Views:

More Releases from DelveInsight Business Research LLP

Ovarian Cancer Pipeline Drugs Report 2025: Innovative Drug Developments and Ongoing Clinical Studies Uncovered
Ovarian Cancer Pipeline Drugs Report 2025: Innovative Drug Developments and Ongo …
DelveInsight's "Ovarian Cancer Pipeline Insight 2025" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Ovarian Cancer pipeline landscape. It covers the Ovarian Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ovarian Cancer Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious about the latest updates in
Endometriosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 18+ Companies and 20+ Therapies | DelveInsight
Endometriosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring …
DelveInsight's "Endometriosis Pipeline Insight 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Endometriosis pipeline landscape. It covers the Endometriosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Endometriosis Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive
HPV16+ Cancer Pipeline Drugs Report 2025: Emerging Therapies, Clinical Trials, and Market Insights by DelveInsight
HPV16+ Cancer Pipeline Drugs Report 2025: Emerging Therapies, Clinical Trials, a …
DelveInsight's, "Human papillomavirus 16-positive (HPV16+) cancers Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Human papillomavirus 16-positive (HPV16+) cancers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest
Digital Biomarkers Market Size Report 2032: Enhancing Trial Efficiency, Accuracy, and Global Pharma Innovation
Digital Biomarkers Market Size Report 2032: Enhancing Trial Efficiency, Accuracy …
DelveInsight's Digital Biomarkers Market Insights Report 2032 provides the current and forecast market analysis, individual leading Digital Biomarkers Companies market shares, challenges, Digital Biomarkers Market Drivers, barriers, trends, and key market Digital Biomarkers companies in the market. To read more about the latest highlights related to the Digital Biomarkers Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/digital-biomarkers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Digital Biomarkers Market

All 5 Releases


More Releases for Behçet

Behcet's Disease Market to Show Remarkable Growth Trends from 2024 to 2034, Delv …
DelveInsight's "Behcet's Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Behcet's Disease, historical and forecasted epidemiology as well as the Behcet's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Behcet's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Behcet's Disease Market Forecast https://www.delveinsight.com/sample-request/behcets-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Behçet's Disease FDA Approvals, Pipeline Insights, and Companies 2024 | AbbVie, …
DelveInsight's, "Behçet's Disease Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Behçet's Disease pipeline landscape. It covers Behçet's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers Behçet's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Request a sample and discover the recent advances
Behçet's Disease Pipeline Outlook Report 2024 | Latest Drug Approvals, FDA, Cli …
DelveInsight's, "Behçet's Disease Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Behçet's Disease pipeline landscape. It covers Behçet's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers Behçet's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Behçet's Disease Pipeline Report •
Behçet's Disease Pipeline Outlook, FDA Approvals, Clinical Trials, and Companie …
DelveInsight's, "Behçet's Disease Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Behçet's Disease pipeline landscape. It covers Behçet's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers Behçet's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Behçet's Disease Pipeline Report • DelveInsight's
Neutrophilic Dermatosis Market 2023 Segments Analysis by Top Key Players: Viatri …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Neutrophilic Dermatosis Market. The Neutrophilic Dermatosis Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy. The Neutrophilic Dermatosis
Behçet's syndrome Market to Witness Growth by (2022-2032), Estimates DelveInsig …
Behçet's syndrome also known as Bycet disease is a rare chronic, relapsing and debilitating inflammatory multisystem disease of unknown etiology characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. DelveInsight's "Behçet syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Behçet syndrome, historical and forecasted epidemiology as well as the Behçet syndrome market trends in the United States, EU5